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Abstract
Background: Hip replacement (arthroplasty) surgery is a highly successful treatment for patients with severe
symptomatic arthritis of the hip joint. For older patients, several designs of Total Hip Arthroplasty have shown
excellent results in terms of both function and value for money. However, in younger more active patients, there is
approximately a 50% failure rate at 25 years for traditional implants. Hip resurfacing is a relatively new arthroplasty
technique. In a recent review of the literature on resurfacing arthroplasty it was concluded that the short-term
functional results appear promising but some potential early disadvantages were identified, including the risk of
femoral neck fracture and collapse of the head of the femur.The aim of the current study is to assess whether
there is a difference in functional hip scores at one year post-operation between Total Hip Arthroplasty and
Resurfacing Arthroplasty. Secondary aims include assessment of complication rates for both procedures as well cost
effectiveness.
Methods/design: All patients medically fit for surgery and deemed suitable for a resurfacing arthroplasty are
eligible to take part in this study. A randomisation sequence will be produced and administered independently.
After consenting, all patients will be clinically reviewed and hip function, quality of life and physical activity level
will be assessed through questionnaires. The allocated surgery will then be performed with the preferred
technique of the surgeon. Six weeks post-operation hip function will be assessed and complications recorded.
Three, six and 12 months post-operation hip function, quality of life and physical activity level will be assessed.
Additional information about patients’ out-of-pocket expenses will also be collected.
Trial registration: Current Controlled Trials ISRCTN33354155
UKCLRN portfolio ID 4093
Background
Hip arthroplasty is a procedure which has been per-
formed by orthopaedic surgeons for decades, with
improvements to the procedure and the implants being
made almost continuously over that time. For older
patients, several designs of Total Hip Arthroplasty
(THA) have shown excellent results in terms of both
function and value for money [1]. However, in younger
more active patients, there is an approximate 50% failure
rate at 25 years for traditional implants [2]. Modern
THA designs with hard bearing surfaces may improve
upon these results [3], but long-term evidence is lacking.
The early results of Resurfacing Arthroplasty (RSA), a
new technique where the proximal femoral anatomy is
preserved, suggest a 98% survival at five years [4]; which
is as good as any of the existing THA’s [1]. However, no
long-term data exists. In a recent review of the literature
on RSA it was concluded that although the short-term
functional results appear promising, some potential early
disadvantages were identified; including risk of femoral
neck fracture, avascular necrosis of the head of the
femur and acetabular bone stock sacrifice [5].
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performed comparing the traditional techniques of THA
with the resurfacing technique. These studies have
focused on the technical aspects of the procedure, such
as the position of the implants or the amount of bone
removed during the resurfacing procedure [6,7]. There
are currently no published results of randomised trials
comparing these two different methods of hip arthro-
plasty using hip function, activity level and patient qual-
i t yo fl i f ea st h ep r i m a r yo u t c o m em e a s u r e .I nan o n -
randomised study, Pollard et al. [8] reported no differ-
ence in the Oxford hip score or the rate of revision
between RSA and THA, however patients in the RSA
group where shown to have higher activity levels after
the procedure and were more likely to be involved in
activities such as running and heavy manual labour.
Furthermore, quality of life scores were found to be
higher in the RSA group compared to the THA group.
In another recent non-randomised study similar results
were reported, with higher activity scores and range of
movement scores for the resurfacing group [9]. In this
study complication rates and reoperation rates at 2 year
follow-up were the same for the two techniques, how-
ever the study design was poor as the two treatment
groups were not comparable with regards to sex, age
and pre-operative functional scores. To provide sur-
geons and patients with accurate information regarding
early function and complication rates, we feel that it is
essential to perform a randomised trial comparing THA
with RSA.
The null hypothesis for this trial is that there is no
difference in functional hip scores (Harris and Oxford
Hip score) at one year post-operation between Total
Hip Arthroplasty and Resurfacing Arthroplasty.
Methods/design
Design
This is a single-blind randomised controlled trial. This
study has been reviewed by the Coventry Research
Ethics Committee under reference number 07/Q2802/
26. The study was approved on the 9
th of May 2007.
The research carried out is in compliance with the Hel-
sinki Declaration.
Study participants
Inclusion criteria
The only eligibility criterion for participation in this
study is that the patient is medically fit for an operation
and suitable for a RSA (all patients that are suitable for
RSA are also suitable for a THA). These broad eligibility
criteria should ensure that the results of the study can
readily be generalised to the wider population.
Exclusion criteria
Contra-indications to surgery, defined as: (i) severe cardiac
impairment, e.g. heart or valve replacement, arrhythmia,
previous myocardial infarction, (ii) severe respiratory
impairment, e.g. chronic obstructive pulmonary disease,
asthma that has required hospital admission, or (iii) any
other systemic medical condition that would produce a
specific contraindication to a general anaesthetic.
Evidence that the patient would be unable to adhere
to trial procedures or complete questionnaires, such as
dementia or intravenous drug abuse
If a recruited patient requires a contra-lateral hip
replacement during the trial period, this second hip can-
not be included in the study (i.e cannot be randomised)
since the result of this intervention would not be inde-
pendent from the first intervention.
Post randomisation withdrawals
Participants may withdraw from the trial at any time
without prejudice. If patients decide to have the treat-
ment to which they were not randomised, participants
will be followed-up wherever possible and data collected
as per the protocol until the end of the trial. The pri-
mary analysis will be on an intention-to-treat basis with
a secondary per-protocol analysis. If patients decide to
have neither treatment, they will be withdrawn from the
trial and not included in the analysis.
The two treatments in this study are THA and RSA.
Each patient will undergo the allocated surgery accord-
ing to the preferred technique of the operating surgeon.
The surgeons involved in the study use a variety of sur-
gical approaches to the hip joint: anterolateral, posterior
and, for the resurfacing patients, the Ganz approach.
Some surgeons use an uncemented THA for younger
more active patients whilst others prefer a more tradi-
tional cemented design or a ‘hybrid’ of the two. In the
same way, some surgeons cement the femoral compo-
nent of a RSA while others prefer an uncemented
component.
In summary, the details of the surgery will be left
entirely to the discretion of the supervising surgical con-
sultant to ensure that the results of the trial can be gen-
eralised to as wide a group of patients as possible.
The Study intervention
Total Hip Arthroplasty
In a THA, the femoral head is removed along with the
majority of the femoral neck. The femoral shaft is
‘reamed’ to open up the femoral canal. The femoral
component is then inserted into the canal and the
articulating femoral head is placed onto the neck of the
femoral component.
Resurfacing Arthroplasty
In a RSA, the articular surfaces of the femoral head are
removed but the neck is left in-situ. The femoral com-
ponent is then impacted onto the patient’s own femoral
neck.
In both forms of Arthroplasty, the acetabulum is
reamed and the acetabular component inserted into the
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right side and a RSA on the left side.
Rehabilitation
Standardised rehabilitation plans will be implemented
for all of the patients; as outlined in the University Hos-
pitals Coventry and Warwickshire NHS Trust ‘Hip
Replacement: A Guide for Patients’ booklet. This
includes information on early exercises, precautions to
be followed for the first three months, functional activity
and later stage exercises. A photocopy of the ‘joint reha-
bilitation discharge letter’ will be made as proof that all
of the patients completed these tasks to a standard level
before discharge.
Follow-up
Patients will continue in routine clinical follow-up, as
per their surgeon’s practice. For this trial, the primary
outcome point will be at one year, with other planned
assessments at six weeks, 3 months and six months after
operation. At all these occasions patients will come to
the clinic to be reviewed by the research associate and if
necessary a doctor.
Study objectives
There are three main objectives of this randomised con-
trolled trial:
1. To quantify and draw inferences on observed dif-
ferences in primary and secondary outcomes mea-
sures between the trial treatment groups at one year
post-operatively.
2. To detemine the complication rate of Resurfacing
Hip Arthroplasty versus Total Hip Arthroplasty at
one year post-operatively.
3. To investigate, using appropriate statistical and
economic analysis methods, the resource use, and
thereby the cost effectiveness, of Resurfacing Hip
Arthroplasty versus Total Hip Arthroplasty.
Outcome measures
This study has two primary outcome measures; the
Oxford Hip Score [10] and the Harris Hip Score [11].
T h eO x f o r dH i pS c o r ei sav a l i d a t e dq u e s t i o n n a i r e
which is self-administered. It consists of 12 items related
to daily tasks directly influenced by poor hip function.
The Harris Hip score is also a hip function question-
naire which includes items reflecting a patient’s ability
to perform normal daily activities but also contains
objective measurements such as range-of-movement.
Three secondary outcome measures will be used in
this trial; (i) EuroQol 5D (EQ-5D): A validated quality
of life questionnaire consisting of 5 questions related to
daily activities scored on a 3-point ordinal score scale.
Answers can be combined using published algorithms to
obtain health-related quality of life values (ii) Disability
Rating Index, a self-administered, 12-item VAS ques-
tionnaire assessing the patient’s own rating of disability
and (iii) Paffenbarger Physical Activity Questionnaire,
this questionnaire assesses the number of calories a
patient expends on leisure and physical activities built
on an assessment of energy spent on average week and
weekend days, as well as additional energy spent during
sporting activities throughout the year. All complica-
tions will be recorded during the course of the trial.
Resource use will be monitored for the economic ana-
lysis. NHS costs associated with each arm of the trial
will be estimated using data from both national sources
(NHS reference costs, PSSRU reference costs [12]) and
the finance departments of the hospitals and services
concerned. The cost consequences following discharge,
including NHS costs and patients’ out-of-pocket
expenses will be recorded via a short questionnaire
which will be administered at 3, 6 and 12 months post
surgery. Patient self-reported information on service use
has been shown to be accurate in terms of intensity of
use of different services [13].
In this study, we will use techniques common in long
term cohort studies to ensure minimum loss at recruit-
ment, such as collection of multiple contact addresses
and telephone numbers, mobile telephone numbers and
email addresses. Every possible effort will be made to
minimise loss to follow-up, with a target of complete
follow-up. Using these techniques, we are confident that
loss will not exceed 10%. In the event of a participant
being lost to the final follow-up at one year, we will
consider, on the advice of the trial statistician, imputing
missing primary outcome data from interim scores.
A system of reminders will be instituted to ensure that
return to clinic at three, six and twelve months is as
complete as possible. The Research Associate will phone
participants to make an appointment, after two weeks
non-response a letter will be send out to the patient.
The letter will be followed up by phone call after 1-2
Figure 1 X-ray showing a Total Hip Arthroplasty (THA) and a
Resurfacing Arthroplasty (RSA).
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will be classed as a ‘non-responder’ and the case closed.
Sample size
Previous work has shown the Oxford Hip Score (OHS)
and the Harris Hip Score (HHS) to be reliable measures
of hip function after surgery, as measured by Cronbach’s
alpha statistic for internal consistency [10,14]. Correla-
tion analysis has indicated that both measures are repro-
ducible, i.e. their test-retest reliability is good, and
previous studies [15] have shown them to be strongly
correlated, indicating that both scoring systems are mea-
suring the same latent characteristic (hip function).
However, the self-administered OHS has achieved much
higher follow-up rates than the more widely used HHS
[15]. Therefore, in order to provide the best assessment
of patient experience of hip function after surgery and
also to allow dissemination of the results of this trial to
as wide a potential audience as possible in resulting
publications, we prudently choose to use both the OHS
and the HHS as primary outcome measures.
Harris Hip Score. There is less available specific infor-
mation on previously observed variability for the HHS,
than for the OHS. Assuming Normally distributed
scores, the required numbers of patients in each arm of
the trial are shown in Table 1, based on an independent
samples t-test (at the 5% level) for assumed standard
deviations (SD) of 13 and 15 [15] and minimum clini-
cally important differences (MCIDs) of 7 and 10 [16]
(PS, power and sample size software, available at http://
biostat.mc.vanderbilt.edu/wiki/Main/PowerSampleSize
The minimum clinically important differences used for
this sample size calculation give effect sizes of around
0.6; a medium to large effect size using the conventional
descriptions of these terms [17]. More reliable data for
determination of the MCID is available for the OHS.
Oxford Hip Score. The best estimate for the standard
deviation for the OHS is 9 and the MCID is between 5
and 7 points on the OHS scale, calculated from a pre-
vious comprehensively reported study [18]. Using these
estimates the required numbers of patients in each arm
of the study, for a two-sample t-test (at the 5% level) are
shown in Table 2.
The results for the OHS and the HHS at the 5% sig-
nificance level, based on the best available estimates of
MCID (5 and 7 score points respectively) are very simi-
lar. Both scores are intended to measure patient hip
function, so it is not unexpected that the sample sizes
obtained using these scores give very similar results. An
adjustment to the significance level for multiple compar-
isons resulted in only a small increase (2-5 patients) in
the required numbers.
In summary, this study will use two primary outcome
measures the Oxford Hip Score and the Harris Hip
Score. The aim will be to recruit 78 patients in each
group as this will provide sufficient participants to
obtain a power of 90% for both primary outcome mea-
sures. With an allowance for 10% drop-out, the total
number of patients required will be 172. If recruitment
proves to be problematic during the course of the trial,
then with the agreement of the trial steering committee
the target will be lowered and the more usual 80%
power level will be considered sufficient. For this sce-
nario, the total number of patients required will be 120
(including 10% for drop-out).
Randomisation
A randomisation sequence has been independently gen-
erated on a computer. The sequence is stratified by
supervising consultant orthopaedic surgeon. The rando-
misation sequence will be held by the Clinical Trials
Unit of the University of Warwick. After patients have
consented to take part in the trial, pre-operation out-
come scores will be collected. Thereafter, the randomi-
sation officer will be alerted by telephone of a new
enrolment. The randomisation officer will provide the
surgeons secretary with the treatment allocation for the
patient which will then be entered onto the hospital
system.
Blinding
Before this trial was designed, patients undergoing res-
urfacing arthroplasty of the hip in our department were
given a different pre-operative information sheet from
those having a total hip arthroplasty; this reflected the
existing evidence regarding the different risk/benefit
profile of the two procedures. Therefore, we do not con-
sider it ethical to blind the patients to their treatment
allocation within the trial. The patients will be informed,
by letter, of their treatment allocation in the week after
they have given their consent. However, we will collect
pre-operative information about the patients’ preference
for one or other treatment.
Table 1 Patient number required for MCID in Harris Hip
Score at different power levels.
MCID = 7 MCID = 10
Power 80% 90% 80% 90%
SD
13 55 73 28 37
15 73 97 36 48
MCID: Minimum clinically important difference
Table 2 Patient number required for minimum MCID in
Oxford Hip Score at different power levels.
MCID = 5 MCID = 7
Power 80% 90% 80% 90%
Sample size 52 69 27 36
MCID: Minimum clinically important difference
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treatment but will take no part in the post-operative
assessment of the patients.
The research associate who performs the pre- and
post- treatment outcome measurements will be blind to
treatment allocation throughout the entire study.
Patients will be asked not to discuss their allocated
treatment with the research associate.
Statistical analysis
The main analysis will investigate differences in the pri-
mary outcome measures, the Harris Hip Score and the
patient-reported Oxford Hip Score, between the two
treatment groups on an intention-to-treat basis. The dif-
ferences between treatment groups will be assessed
using an independent samples t-test at 12 months post-
operatively at the 5% level. Test levels, for the two pri-
mary outcome measures will be adjusted using the
methods of Holm-Bonferroni [19] to allow for the mul-
tiple comparisons. A linear regression analysis will also
be used to quantify the effects of the treatment groups
on each of the primary outcome measures, after adjust-
ing for the effects of a range of other important, poten-
tially confounding, factors (e.g. age, gender) recorded for
each patient. Subsidiary analyses will report results of
tests for secondary outcome measures and primary out-
come measures at interim occasions. Interim analyses
will be performed only where directed by the Data
Monitoring Committee.
The second main statistical objective of the trial is to
determine, and compare, the complication rate of RSA
and THA at one year post-operatively. All complications
will be recorded during the trial, and rates will be deter-
mined at 12 months post-operatively and compared
between treatment groups using a chi-squared (at the
5% level).
Economic analysis
The economic evaluation will estimate the incremental
cost effectiveness of RSA compared to THA from the
perspective of the UK NHS. A within trial (12 month)
analysis will be conducted, with lifetime results extrapo-
lated from trial data, registry data, and the literature
using a patient level simulation model. These analyses
will have common features: both will use a quality-
adjusted life-year (QALY) outcome measure based on
EQ-5D data and the 10 year MVH TTO tariff [20]; both
will use a payer (NHS and Social Services) perspective
for the main case analysis; costs will be obtained from
resource using national databases (NHS Reference
Costs, the BNF, and PSSRU Costs of Health and Social
Care) and local data sources (UHCW finance
department).
The within trial analysis will consider cost-effective-
ness within the first 12 months of treatment. This analy-
sis will be based on quality of life data collected at
d i s c h a r g e( b a s e l i n e )a n da t3 ,6 ,a n d1 2m o n t h sp o s t
operatively, with QALYs obtained by calculating the
area under the curve. Resource usage will be estimated
from trial forms plus patient questionnaires detailing
other NHS contacts and personal expenditures within
the trial period, with costs assessed as above.
As hip replacement and failure of hip replacements
may have an impact upon mortality as well as morbidity,
it will be necessary to adopt a lifetime time horizon to
estimate the full incremental value of RSA compared to
THA. Therefore we will construct a patient-level deci-
sion analytic cost effectiveness model to estimate the
expected incremental cost per life year gained for RSA
compared to THA. Whilst the trial dataset will be used
to provide parameters for several states, the main data
sources for the extrapolation will come from existing lit-
erature and registries as the model horizon greatly
exceeds the trial length. The model will comprise states
specific to both RSA and THA (surgery, recovery, suc-
cess and failure), with adjustments for THA revision
surgeries (as feasible). Quality of life figures will be
obtained from a combination of trial data and literature/
registries. Mortality will be represented using age/gender
specific rates, with additional mortality assigned in sur-
gical, recovery and failure states (as feasible). Failure
rates for devices will be based on survival analysis, with
the type and complexity of relationships determined by
Bayesian decision criteria. Costs will be obtained from
the within-trial analysis by status and used to inform
state-specific costs, with existing literature and expert
judgement used where necessary. The model will use a
standard discount rate of 3.5 and parameter uncertainty
will be addressed through probabilistic sensitivity analy-
sis, with any inflation-adjustments based on the HCHS
Pay and Prices Index. Wherever possible, the results of
all analyses will be presented in a simple, easy to follow
manner using standard techniques within economic eva-
luation. Outputs of each analysis will be presented as
Cost Effectiveness Acceptability Frontiers and Expected
Net Benefit figures assuming that the cost-effectiveness
threshold lies at £30,000 per QALY.
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